Aliases & Classifications for Somatization Disorder

MalaCards integrated aliases for Somatization Disorder:

Name: Somatization Disorder 12 74 15 71 32
Somatoform Disorders 43 32
Polysomatising Disorder 12
Somatisation Disorder 12
Somatoform Disorder 71
Briquet's Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13918
ICD9CM 34 300.81
MeSH 43 D013001
SNOMED-CT 67 60368009 9514005
ICD10 32 F45 F45.0
UMLS 71 C0037650 C0520482

Summaries for Somatization Disorder

Disease Ontology : 12 A somatoform disorder that involves persistently complaints of varied physical symptoms that have no identifiable physical origin.

MalaCards based summary : Somatization Disorder, also known as somatoform disorders, is related to tic disorder and social phobia, and has symptoms including multiple somatic complaints An important gene associated with Somatization Disorder is SOCS6 (Suppressor Of Cytokine Signaling 6), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Pregabalin and Histamine have been mentioned in the context of this disorder. Affiliated tissues include prostate, brain and testes.

Wikipedia : 74 Somatization disorder is a mental disorder characterized by recurring, multiple, and current, clinically... more...

Related Diseases for Somatization Disorder

Diseases related to Somatization Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 211)
# Related Disease Score Top Affiliating Genes
1 tic disorder 30.3 SLC6A4 HTR2A
2 social phobia 30.3 SLC6A4 OXT IVL HTR1A
3 obsessive-compulsive personality disorder 30.1 SLC6A4 HTR2A
4 acute stress disorder 30.1 SLC6A4 CRH
5 trigeminal neuralgia 30.0 TAC1 SLC6A4
6 fibromyalgia 30.0 SLC6A4 HTR2A CRH
7 phobia, specific 29.8 SLC6A4 IVL HTR1A
8 adjustment disorder 29.7 SLC6A4 SCLY HTR2A DCXR
9 post-traumatic stress disorder 29.5 SLC6A4 HTR2A CRH
10 bruxism 29.4 TAC1 SLC6A4 HTR2A HTR1A
11 body dysmorphic disorder 29.3 SLC6A4 HTR2A
12 depression 29.1 SLC6A4 HTR2A HTR1A CRH
13 eating disorder 29.1 SLC6A4 HTR2A CRH
14 personality disorder 29.1 SLC6A4 HTR2A HTR1A CRH
15 chronic fatigue syndrome 29.0 SLC6A4 HTR2A HTR1A CRH
16 alexithymia 28.9 SLC6A4 OXT HTR1A
17 generalized anxiety disorder 28.9 SLC6A4 HTR2A HTR1A
18 hypochondriasis 28.9 SLC6A4 IVL HTR2A HTR1A
19 neurotic disorder 28.8 SLC6A4 HTR2A HTR1A
20 dissociative disorder 28.7 SLC6A4 SCLY OXT HTR2A
21 mood disorder 28.7 SLC6A4 HTR2A HTR1A CRH
22 postpartum depression 28.6 SLC6A4 SCLY OXT HTR1A CRH
23 substance abuse 28.6 SLC6A4 HTR2A HTR1A CRH
24 sleep disorder 28.6 SLC6A4 HTR2A HTR1A
25 borderline personality disorder 28.5 SLC6A4 HTR2A HTR1A CRH
26 alcohol use disorder 28.5 SLC6A4 HTR2A HTR1A CRH
27 irritable bowel syndrome 28.5 TAC1 SLC6A4 HTR2A HTR1A CRH
28 dysthymic disorder 28.3 SLC6A4 SCLY IVL HTR2A HTR1A CRH
29 panic disorder 28.2 TAC1 SLC6A4 HTR2A HTR1A CRH
30 mental depression 28.1 SLC6A4 SCLY OXT HTR2A HTR1A CRH
31 sexual disorder 28.1 SLC6A4 OXT HTR2A HTR1A
32 alcohol dependence 28.0 SLC6A4 OXT HTR2A HTR1A CRH
33 psychotic disorder 28.0 SLC6A4 OXT HTR2A HTR1A
34 anxiety 28.0 TAC1 SLC6A4 OXT HTR2A HTR1A CRH
35 agoraphobia 28.0 SLC6A4 SCLY IVL HTR2A HTR1A
36 anorexia nervosa 27.9 SLC6A4 OXT HTR2A HTR1A CRH
37 major depressive disorder 27.8 TAC1 SLC6A4 OXT HTR2A HTR1A CRH
38 alzheimer disease 27.7 SLC6A4 REG1A OXT HTR2A HTR1A CRH
39 obsessive-compulsive disorder 27.7 SLC6A4 OXT HTR2A HTR1A CRH
40 endogenous depression 27.4 SLC6A4 SCLY OXT HTR2A HTR1A CRH
41 disease of mental health 27.4 TAC1 SLC6A4 OXT HTR2A HTR1A CRH
42 bipolar disorder 27.4 SLC6A4 HTR2A HTR1A CRH
43 migraine with or without aura 1 27.2 TAC1 SLC6A4 OXT HTR2A HTR1A CRH
44 phobic disorder 27.0 SLC6A4 SCLY OXT IVL HTR2A HTR1A
45 dissociative seizures 11.5
46 psychogenic movement 11.5
47 somatoform disorder 10.8
48 neurogenic bowel 10.2 TAC1 DCXR
49 dental anomalies and short stature 10.2 SCLY IVL
50 alcoholic psychosis 10.1 SLC6A4 HTR2A

Comorbidity relations with Somatization Disorder via Phenotypic Disease Network (PDN): (show all 13)


Acute Cystitis Anxiety
Dependent Personality Disorder Dysthymic Disorder
Esophagitis Generalized Anxiety Disorder
Histrionic Personality Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Irritable Bowel Syndrome Major Depressive Disorder
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Somatization Disorder:



Diseases related to Somatization Disorder

Symptoms & Phenotypes for Somatization Disorder

UMLS symptoms related to Somatization Disorder:


multiple somatic complaints

Drugs & Therapeutics for Somatization Disorder

Drugs for Somatization Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 298)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
2
Histamine Approved, Investigational Phase 4 51-45-6 774
3
Flunarizine Approved Phase 4 52468-60-7 941361
4
Cycloserine Approved Phase 4 68-41-7 401 6234
5
Polyestradiol phosphate Approved Phase 4 28014-46-2
6
Tibolone Approved, Investigational Phase 4 5630-53-5
7
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
8
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
9
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
10
Citalopram Approved Phase 4 59729-33-8 2771
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
13
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
14
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
15
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
16 Anti-Anxiety Agents Phase 4
17 Tranquilizing Agents Phase 4
18 calcium channel blockers Phase 4
19 Calcium, Dietary Phase 4
20 Vasodilator Agents Phase 4
21 Histamine H1 Antagonists Phase 4
22 Histamine Antagonists Phase 4
23
Histamine Phosphate Phase 4 51-74-1 65513
24 Antitubercular Agents Phase 4
25 Renal Agents Phase 4
26 Antibiotics, Antitubercular Phase 4
27 Anti-Infective Agents, Urinary Phase 4
28 Antimetabolites Phase 4
29 Estrogens Phase 4
30 Antihypertensive Agents Phase 4
31 Estradiol 17 beta-cypionate Phase 4
32 Contraceptive Agents Phase 4
33 Selective Estrogen Receptor Modulators Phase 4
34 Anabolic Agents Phase 4
35 Contraceptives, Oral Phase 4
36 Contraceptive Agents, Male Phase 4
37
Medroxyprogesterone Phase 4 520-85-4 10631
38 Antineoplastic Agents, Hormonal Phase 4
39 Androgens Phase 4
40 Estrogen Receptor Modulators Phase 4
41 Androgen Antagonists Phase 4
42 Estradiol 3-benzoate Phase 4
43 Neurotransmitter Agents Phase 4
44 Psychotropic Drugs Phase 4
45 Antidepressive Agents Phase 4
46 Serotonin Uptake Inhibitors Phase 4
47 abobotulinumtoxinA Phase 4
48 Acetylcholine Release Inhibitors Phase 4
49 Neuromuscular Agents Phase 4
50 Botulinum Toxins Phase 4

Interventional clinical trials:

(show top 50) (show all 234)
# Name Status NCT ID Phase Drugs
1 Neurologic Signatures of Chronic Pain Disorders Unknown status NCT02747940 Phase 4 flunarizine and/or pregabalin
2 Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
3 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy, Alone or in Combination: a Single-blind, Randomized, Controlled Clinical Trial. Completed NCT01250184 Phase 4 Lidocaine injection
4 The Impact of Different Hormone Therapy Regimens on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder Recruiting NCT01822288 Phase 4 Tibolone;Estradiol & medroxyprogesterone acetate
5 Using Saline for Myofascial Pain Syndromes (USAMPS) Terminated NCT02120261 Phase 4 Normal Saline;Lidocaine Hydrochloride;Triamcinolone acetonide
6 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study Terminated NCT01879930 Phase 4 doxycycline;placebo
7 Sinusitis and Facial Pain Disorders Anti-Depression Trial Terminated NCT00754793 Phase 4 escitalopram;placebo
8 Botox (Botulinum Toxin A) as a Treatment for Chronic Male Pelvic Pain Syndrome: A Randomized Placebo Controlled Trial Terminated NCT00194623 Phase 4 Botulinum Toxin A (Botox)
9 A Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome in Personality, Helicobacter Pylori Infection, Gastric Emptying and Response to Lansoprazole Treatment Withdrawn NCT00673972 Phase 4
10 Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery Unknown status NCT02390505 Phase 3 Vitamin C;Placebo
11 A Randomized, Placebo-controlled Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3 Pregabalin;Placebo
12 Double-Blind Randomized Controlled Trial: Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb Unknown status NCT01612364 Phase 3
13 Prospective, Double-blind, Randomised, Placebo-controlled, Cross-over Study to Investigate the Effect of Intravenous Immunoglobulins on Complex Regional Pain Syndrome (CRPS, M. Sudeck) Unknown status NCT00949065 Phase 3
14 Treatment of Somatization in Primary Care Completed NCT00050583 Phase 3
15 Treatment of Patients With Chronic Functional Disorders. A Randomized Controlled Trial of Specialized Treatment Compared to Usual Care. Completed NCT00132197 Phase 2, Phase 3
16 Treating Refractory Symptoms in Primary Care (Hypochondriasis: Diagnosis, Description and Medical Care) Completed NCT00368212 Phase 3
17 A 16-week Prospective Randomised Double-blind Study on Facilitation of DYSPORT® Effect on Myofascial Pain Syndrome (MPS) by Electrical Stimulation. Completed NCT00246142 Phase 3
18 Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidamide in the Treatment of Complex Regional Pain Syndrome Type1 Completed NCT00166452 Phase 3 Lenalidamide
19 Efficacy of a Biopsychosocial Treatment for Somatizing Patients Carried Out by the General Practitioner Completed NCT00130988 Phase 3
20 Effectiveness of Diacutaneous Fibrolysis Technique on Pain, Range of Motion, Strength and Function in Patients With Patellofemoral Pain Syndrome Completed NCT02379364 Phase 3
21 Phase 3 Study of a Standardized Pollen Extract Preparation (Cernilton) in Patients With Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome Completed NCT00919893 Phase 3 Cernilton;Placebo
22 Dysfunctional Illness-related Cognitions in Individuals With Hypochondriasis and Change Thereof Completed NCT01119469 Phase 3
23 Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder Completed NCT00149799 Phase 3 Escitalopram;Placebo
24 A Verification Study of JNS020QD in Patients With Post-herpetic Neuralgia, Complex Regional Pain Syndrome (CRPS) or Postoperative Pain Syndrome Completed NCT01008553 Phase 3 Fentanyl;Placebo
25 Pain Exposure Physical Therapy Or Conservative Therapy for Patients With Complex Regional Pain Syndrome Type I Completed NCT00817128 Phase 2, Phase 3
26 A Prospective Randomized Study Comparing the Outcome of Electrical Stimulation of Vastus Medialis Obliquus Muscle and Physical Therapy vs Only Physical Therapy But no Electrical Stimulation in Patients With Patellofemoral Pain Syndrome Recruiting NCT03184545 Phase 3
27 Comparison of Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles in the Management of Myofascial Pain Disorder: A Randomized Clinical Trial Recruiting NCT03223298 Phase 3 Botulinum toxin type A;0.9% Sodium Chloride Injection
28 The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the Src Homology 2-containing Inositol-5'-Phosphatase 1 (SHIP1) Pathway in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period Active, not recruiting NCT02858453 Phase 3 AQX-1125 100 mg;AQX-1125 200 mg;Placebo
29 A Prospective Randomized Controlled Pilot Study Nitrous Oxide for the Treatment of Complex Regional Pain Syndrome Enrolling by invitation NCT03879538 Phase 3 Nitrous Oxide;Oxygen
30 Placebo-controlled Efficacy and Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS) Terminated NCT03560986 Phase 3 Neridronic acid;Placebo
31 Pharmacovigilance in Gerontopsychiatric Patients Terminated NCT02374567 Phase 3 Phenobarbital;Phenytoin;Carbamazepine;Oxcarbazepine;Valproic Acid;Lamotrigine;Topiramate;Gabapentin;Levetiracetam;Pregabalin;Lacosamide;Clonazepam;Biperiden;Levomepromazine;Fluphenazine;Perphenazine;Perazine;Thioridazine;Haloperidol;Melperone;Pipamperone;Bromperidol;Benperidol;Sertindole;Ziprasidone;Flupentixol;Chlorprothixene;Zuclopenthixol;Fluspirilene;Pimozide;Clozapine;Olanzapine;Quetiapine;Sulpiride;Tiapride;Amisulpride;Prothipendyl;Risperidone;Aripiprazole;Paliperidone;Diazepam;Oxazepam;Lorazepam;Bromazepam;Clobazam;Alprazolam;Hydroxyzine;Buspirone;Chloral Hydrate;Flurazepam;Nitrazepam;Triazolam;Lormetazepam;Temazepam;Midazolam;Brotizolam;Zopiclone;Zolpidem;Zaleplon;Melatonin;Clomethiazole;Diphenhydramine;Promethazine;Imipramine;Clomipramine;Opipramol;Trimipramine;Amitriptyline;Nortriptyline;Doxepin;Maprotiline;Amitriptyline oxide;Fluoxetine;Citalopram;Paroxetine;Sertraline;Fluvoxamine;Escitalopram;Tranylcypromine;Moclobemide;Mianserin;Trazodone;Mirtazapine;Bupropion;Venlafaxine;Reboxetine;Duloxetine;Agomelatine;Pyritinol;Piracetam;Donepezil;Rivastigmine;Galantamine;Memantine;Nicergoline;Acamprosate;Lithium
32 Injection of Botulinum Toxin Type A Into the External Urethral Sphincter for Male Patients Suffering From Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Cat. III): a Prospective, Double-blind and Placebo-controlled Clinical Trial Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
33 Phase 2 Study - The Use of a Single 5 mg Dose of Zoledronic Acid in Complex Regional Pain Syndrome Patient. Unknown status NCT01788176 Phase 2 Zoledronic acid;Placebo
34 Intra-articular Hyaluronic Acid Injection for Therapy-resistant Patellofemoral Pain Syndrome: an Open-label, Randomized, Delayed-start Clinical Trial Unknown status NCT02613247 Phase 2
35 Cognitive Affective Behavior Therapy for Somatization Completed NCT00149760 Phase 2
36 Treatment of Multi-organ Bodily Distress Syndrome. A Double-blinded Placebo Controlled Trial of the Effects of Imipramine (Stress-3) Completed NCT01518634 Phase 2 Imipramine treatment;Placebo
37 Cognitive Behavior Therapy for Somatization Disorder Completed NCT00276887 Phase 2
38 Evaluation of the Effects of a Body-centered Emotional Stimulation in Healthy Persons Completed NCT01187797 Phase 1, Phase 2
39 A Phase II Multicentre Multinational Prospective Randomised Double-blind Placebo-controlled Study Assessing the Efficacy and Safety of a Single Application of Three Doses of Dysport® in Patients With Upper Back Myofascial Pain Syndrome Completed NCT00134810 Phase 2
40 A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis Completed NCT03282318 Phase 2 ASP6294;Placebo
41 Quadriceps Femoris Strengthening Versus Hamstring Stretching for Patellofemoral Pain Syndrome: A Randomized Clinical Trial. Completed NCT01691170 Phase 1, Phase 2
42 A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00740779 Phase 2 Silodosin 8 mg;Placebo;Silodosin 4 mg
43 A Multicenter, Open-Label Study to Evaluate the Preliminary Safety and Efficacy of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) Completed NCT00067743 Phase 2 Lenalidomide
44 Treatment for Patellofemoral Pain Syndrome Using Knee Abduction Moment-Reducing Footwear Completed NCT01332110 Phase 1, Phase 2
45 An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00701311 Phase 2 CC-10004
46 The Impact of Cardiac Rehabilitation on Angina Frequency, Psychological Morbidity and Quality of Life in Women With Syndrome X Completed NCT00123617 Phase 2
47 7.5% Sinecatechins Ointment, a Botanical Drug Derived From Green Tea, for the Treatment of Significant to Severe Secondary Provoked Vestibulodynia in Sexually Active, Post-Menopausal Women With Vulvovaginal Atrophy Recruiting NCT03682601 Phase 2 Sinecatechins Topical
48 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Adult Subjects With Chronic Complex Regional Pain Syndrome Recruiting NCT03990649 Phase 2 TAK-935;TAK-935 Placebo
49 A Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1 Terminated NCT00109772 Phase 2 lenalidomide;Placebo
50 A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Efficacy and Safety of AQX-1125 (200 mg) in Male Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Terminated NCT03500159 Phase 2 AQX-1125 200 mg;Placebo

Search NIH Clinical Center for Somatization Disorder

Cochrane evidence based reviews: somatoform disorders

Genetic Tests for Somatization Disorder

Anatomical Context for Somatization Disorder

MalaCards organs/tissues related to Somatization Disorder:

40
Prostate, Brain, Testes, Spinal Cord, Bone, Dorsal Root Ganglion, Eye

Publications for Somatization Disorder

Articles related to Somatization Disorder:

(show top 50) (show all 1934)
# Title Authors PMID Year
1
Psychological disturbances in patients with pigmentary disorders: a cross-sectional study. 61
31566833 2020
2
Quantitative Sensory Testing in Patients with Multisomatoform Disorder with Chronic Pain as the Leading Bodily Symptom-a Matched Case-Control Study. 61
31578559 2020
3
Patients with chronic urticaria have a higher risk of psychiatric disorders: a population-based study. 61
31220338 2020
4
[Non specific complaints. Somatization disorder or somatic disease?] 61
31960307 2020
5
Detecting DSM-5 somatic symptom disorder: criterion validity of the Patient Health Questionnaire-15 (PHQ-15) and the Somatic Symptom Scale-8 (SSS-8) in combination with the Somatic Symptom Disorder - B Criteria Scale (SSD-12). 61
30729902 2020
6
Factors influencing adherence to therapeutic recommendations made after diagnostic reassessment of medically unexplained symptoms in children and adolescents. 61
30818976 2020
7
[Internal medicine between soma and psyche : Functional bodily complaints and depressive disorders in outpatient care]. 61
31853579 2020
8
Emotion Regulation Strategies in Depression and Somatization Disorder. 61
30304997 2019
9
Assessing somatization in urologic chronic pelvic pain syndrome. 61
31823813 2019
10
Orthorexic eating behavior in patients with somatoform disorders. 61
31833044 2019
11
Multisensory mechanisms of body perception in somatoform disorders. 61
31644956 2019
12
Mental health conditions diagnosed before bilateral oophorectomy: a population-based case-control study. 61
31479036 2019
13
Addressing Mental Health Concerns in Primary Care: Practices Among Medical Residents in a Rural Setting. 61
30758698 2019
14
The relationship between somatic sense perception levels and comorbid psychiatric diseases in chronic pain patients. 61
31741346 2019
15
The use of melatonin in adult psychiatric disorders: Expert recommendations by the French institute of medical research on sleep (SFRMS). 61
31248601 2019
16
Anxiety is the cause of the worse outcomes of allergic patients after total knee arthroplasty. 61
31722034 2019
17
Implementation of outcome measurement (HoNOS) in an outpatient psychiatric clinic in Sligo/Leitrim mental health service. 61
30980222 2019
18
Mindfulness and Acceptance-Based Group Therapy: An Uncontrolled Pragmatic Pre-Post Pilot Study in a Heterogeneous Population of Female Prisoners. 61
31238758 2019
19
Hospital length of stay among older people treated with flexible and integrative psychiatric service models in Germany. 61
31276239 2019
20
Changes in brain glucose metabolism and connectivity in somatoform disorders: an 18F-FDG PET study. 61
31720787 2019
21
Associations of psychosis-risk symptoms with quality of life and self-rated health in the Community. 61
31586798 2019
22
Posttraumatic stress reactions of underground drivers after suicides by jumping to arriving trains; feasibility of an early stepped care outpatient intervention. 61
30963791 2019
23
[Gastrointestinal somatoform disorders]. 61
31519027 2019
24
Small atrial septal defects are associated with psychiatric diagnoses, emotional distress, and lower educational levels. 61
31136098 2019
25
Association between ambient PM2.5 and emergency department visits for psychiatric emergency diseases. 61
30522934 2019
26
[Sinus Tachycardia in the Adolescent: The Importance of Differential Diagnosis]. 61
31445536 2019
27
Re: Jing et al., the efficacy of cognitive behavioural therapy in somatoform disorders and medically unexplained physical symptoms: A meta-analysis of randomized controlled trials. 61
30819582 2019
28
Individuals with currently untreated mental illness: causal beliefs and readiness to seek help. 61
29335036 2019
29
The prognosis of functional limb weakness: a 14-year case-control study. 61
31167232 2019
30
Voxel-based global-brain functional connectivity alterations in first-episode drug-naive patients with somatization disorder. 61
31121532 2019
31
Evaluation of Risk Factors for ADHD and Co-Morbid Psychiatric Disorders Among the Parents of Children With ADHD. 61
27009925 2019
32
Early maladaptive schemas in patients with somatoform disorders and somatization. 61
30836437 2019
33
Parent-youth conflict as a predictor of depression in adulthood: a 15-year follow-up of a community-based cohort. 61
31302772 2019
34
Pain and gastrointestinal dysfunction are significant associations with psychiatric disorders in patients with Ehlers-Danlos syndrome and hypermobility spectrum disorders: a retrospective study. 61
30923956 2019
35
Large-scale study of Toxoplasma and Cytomegalovirus shows an association between infection and serious psychiatric disorders. 61
30685531 2019
36
Deficits in Theory of Mind and Emotional Awareness in Somatoform Disorders. 61
31391671 2019
37
Profile of home nursing clients with mental health diagnoses: Epidemiological analysis of Australian community home nursing data. 61
30815957 2019
38
Sociomedical problems of overwork-related deaths and disorders in Japan. 61
30977205 2019
39
A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety. 61
31195993 2019
40
Health-related life events in patients with somatic symptom disorders: A case control study. 61
30969143 2019
41
The Neuroanatomy of Somatoform Disorders: A Magnetic Resonance Imaging Study. 61
30119840 2019
42
Physical activity is indirectly associated with pain in college women through associations with somatization and panic disorder symptoms: a cross-sectional study. 61
30905543 2019
43
[The Body Dysmorphic Disorder in Plastic Surgery - A Systematic Review of Screening Methods]. 61
31618775 2019
44
Emotional dysregulation subgroups in patients with adult Attention-Deficit/Hyperactivity Disorder (ADHD): a cluster analytic approach. 61
30948735 2019
45
The prevalence and its correlates of somatization disorder at a quaternary mental health centre. 61
30947092 2019
46
Differential Diagnosis between Anomalous Experiences and Dissociation Disorder Using the Dissociative Disorders Interview Schedule (DDIS). 61
30058948 2019
47
Functional neuroimaging in patients presenting with somatoform disorders: A model for investigating persisting symptoms after tick bites and post-treatment Lyme disease syndrome? 61
30736992 2019
48
Differential diagnostic challenge - Eating disorder, gastroparesis or somatization disorder? - Case report. 61
30948699 2019
49
A study of psychiatric morbidity among school going adolescents. 61
30992616 2019
50
Utilization of Emergency Psychiatry Service in a Tertiary Care Centre in North Eastern India: A Retrospective Study. 61
30983666 2019

Variations for Somatization Disorder

Expression for Somatization Disorder

Search GEO for disease gene expression data for Somatization Disorder.

Pathways for Somatization Disorder

Pathways related to Somatization Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.47 TAC1 SLC6A4 HTR2A HTR1A
2 11.39 SLC6A4 HTR2A HTR1A
3
Show member pathways
10.62 SLC6A4 HTR1A
4 10.25 SLC6A4 HTR2A HTR1A

GO Terms for Somatization Disorder

Biological processes related to Somatization Disorder according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cytosolic calcium ion concentration GO:0007204 9.72 TAC1 OXT HTR2A
2 positive regulation of cell proliferation GO:0008284 9.72 UFL1 REG1A HTR2A HTR1A CRH
3 chemical synaptic transmission GO:0007268 9.67 TAC1 HTR2A HTR1A CRH
4 memory GO:0007613 9.61 SLC6A4 OXT HTR2A
5 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.57 HTR2A HTR1A
6 associative learning GO:0008306 9.56 TAC1 CRH
7 response to pain GO:0048265 9.54 TAC1 CRH
8 vasoconstriction GO:0042310 9.52 SLC6A4 HTR1A
9 positive regulation of ossification GO:0045778 9.51 TAC1 OXT
10 positive regulation of renal sodium excretion GO:0035815 9.49 TAC1 OXT
11 sleep GO:0030431 9.48 OXT HTR2A
12 behavior GO:0007610 9.46 HTR2A HTR1A
13 serotonin receptor signaling pathway GO:0007210 9.4 HTR2A HTR1A
14 sperm ejaculation GO:0042713 9.26 SLC6A4 OXT
15 response to ether GO:0045472 9.16 OXT CRH
16 positive regulation of corticosterone secretion GO:2000854 8.96 TAC1 CRH
17 regulation of serotonin secretion GO:0014062 8.62 HTR1A CRH

Molecular functions related to Somatization Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.26 HTR2A HTR1A
2 G protein-coupled serotonin receptor activity GO:0004993 9.16 HTR2A HTR1A
3 neuropeptide hormone activity GO:0005184 8.96 OXT CRH
4 serotonin binding GO:0051378 8.8 SLC6A4 HTR2A HTR1A

Sources for Somatization Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....